References
1a
Revankar GR.
Robins RK. In Chemistry of Nucleosides
and Nucleotides
Vol. 2:
Townsend LB.
Plenum Press;
New
York:
1994.
p.161-398
1b
Srivastava PC.
Robins RK.
Meyer RB. In Chemistry
of Nucleosides and Nucleotides
Vol. 3:
Townsend LB.
Plenum Press;
New
York:
1994.
p.421-535
1c
Perigaud C.
Gosselin G.
Imbach JL.
Nucleosides
Nucleotides
1992,
11:
903
1d
De Clercq E.
Nucleosides
Nucleotides
1994,
12:
1271
2a
Hori M.
Ito E.
Takida T.
Koyama Y.
Takeuchi T.
Umezawa H.
J. Antibiot.
1964,
17A:
96
2b
Long RA.
Lewis AF.
Robins RK.
Townsend LB.
J.
Org. Chem.
1971,
36:
2443
2c
Lewis AF.
Townsend LB.
J.
Am. Chem. Soc.
1982,
104:
1073
2d
Orozco M.
Canela EI.
Franco R.
Mol.
Pharmacol.
1989,
35:
257
3a
Robins RK.
Townsend LB.
Cassidy F.
Gersrter FG.
Lewis AT.
Miller RL.
J. Heterocycl. Chem.
1966,
3:
110
3b
Koyama G.
Umezawa H.
Antibiot. Ser. A
1965,
18:
175
4a
Ishizuka M.
Sawa T.
Hori S.
Takayama T.
Takeuchi T.
Umezawa H.
J.
Antibiot.
1968,
21:
5
4b
Sheen MR.
Martin FH.
Parks HF.
Mol. Pharmacol.
1970,
6:
255
5
Otter BA.
Patil SA.
Klein RS.
Abstract
CARB 046, the 4th Chemical Congress of North America
and the 202nd American Chemical Society Meeting
ACS;
New
York:
August 1991.
6
Ward DC.
Fuller W.
Reich E.
Proc.
Natl. Acad. Sci. U.S.A.
1969,
62:
581
7a
Gudmundsson KS.
Drach JC.
Townsend LB.
J. Org.
Chem.
1997,
62:
3453
7b
Walker JAII.
Liu W.
Wise DS.
Drach JC.
Townsend LB.
J. Med. Chem.
1998,
41:
1236
8
Marakos P.
Pouli N.
Wise SD.
Townsend LB.
Synlett
1997,
561
9
Chapman D.
Hurst J.
J. Chem. Soc., Perkin Trans.
1
1980,
2398
10
Beumel OF.
Smith WN.
Rubalka B.
Synthesis
1974,
43
11a
Cousineau TJ.
Secrist JA.
J. Org. Chem.
1979,
44:
4351
11b
Timpe W.
Dax K.
Wolf N.
Weidmann H.
Carbohydr. Res.
1975,
69:
51
12 For hemiacetals 3 the
prefix α refers to the position of the glycosidic OH group
relative to the configuration at the reference C-atom (C-4′ in 3; i.e. the methylpyridinyl moiety is in
the β-position). For C-glycosides (no glycosidic OH present),
the prefix α-D refers to the alkyl (or aryl) position relative
to the reference C-atom.
13 Optimized procedure for the preparation
of the hemiacetals 3: To a solution of 1 (0.5 g, 2.72 mmol) in dry THF (30 ml) at -78 °C
was added under argon n-BuLi (4.3 ml,
6.95 mmol, 1.6 M solution in hexanes). The resulting light yellow solution
was stirred at -78 °C for 15 min and the temperature then
raised to -40 °C for 1 h. The orange-colored solution was
then cooled to -78 °C, a solution of the d-ribonolactone 2 (1.4
g, 3.34 mmol) in dry THF (10 ml) was added dropwise and the resulting
mixture was stirred at -78 °C for 1 h and at -40 °C
for an additional 5 h. A saturated ammonium chloride solution was
then added to the reaction mixture to quench the excess n-BuLi. The solvent was vacuum-evaporated, water
was added to the residue and this was extracted with dichloromethane.
The organic extracts were dried (Na2SO4) and
concentrated to dryness to give an oil, which was purified by flash
chromatography (silica gel 20 × 2 cm) using a mixture of
cyclohexane-ethyl acetate, 7:3 v/v as the eluent to
give the isomeric hemiacetals 3 (63%),
together with 4 (6%).
14 The configuration at C-1′ was
assigned on the basis of nOe spectral data. In the case of the β-D anomer clear correlation peaks between
the OH-1′ and the H-2′, H-3′ and H-5′ were observed.
15 In the HMBC spectrum of 4, a strong correlation peak between the
5-aromatic H and the carbon of the methyl group (3
J coupling) is evident. The methyl group
protons correlate also with the aromatic carbons 3,5 (3
J coupling) and 4 (2
J coupling). The methylene group protons
possess a strong correlation with both the anomeric carbon and the carbonyl.
NOESY data provided evidence for the β-conformation, since
we observed correlation peaks between the methylene protons attached
at the anomeric position with H-4′.
16 Data of 3-[(1-hydroxy-2,3,5-tri-
-benzyl)-β-d-ribofurano-syl)acetylamino]-2-methoxy-4-methylpyridine(4): Colorless
oil. 1
-NMR (400 MHz,
CDCl3) δ 1.95 (s, 3 H, 4-CH3), 2.78
(m, 2 H, COCH2), 3.38 (m, 2 H, H-5′), 3.73 (d,
1 H, J2
′
,3
′ = 4.56
Hz, H-2′), 3.85 (m, 1 H, H-3′), 3.99 (s, 3 H, OCH3),
4.29 (m, 1 H, H-4′), 4.32-4.68 (m, 7 H, 3 × CH2-Ph, OH),
6.70 (d, 1 H, J
5,6 = 4.98
Hz, H-5), 7.2-7.4 (m, 15 H, 3 × C6H5),
7.84 (d, 1 H, J6,5 = 4.98 Hz, H-6), 7.94 (br
s, 1 H, D2O exchangeable, NH). 13C
NMR (50 MHz, CDCl3) δ 18.0 (4-CH3),
41.2 (COCH2), 53.3 (CH3O), 69.3 (C-5′),
72.3 (CH2-Ph), 72.6 (CH2-Ph), 73.3 (CH2-Ph),
76.9 (C-3′), 78.9 (C-2′), 80.4 (C-4′),
105.0 (C-1′), 118.9 (C-5), 119.1 (C-3), 127.7 [CH(Ph)],
128.0 [CH(Ph)], 128.2 [CH(Ph)],
128.3 [CH(Ph)], 128.6 [CH(Ph)],
136.7 [C(Ph)], 136.9 [C(Ph)], 137.6 [C(Ph)],
145.6 (C-4), 146.0 (C-6), 158.4 (C-2), 169.2 (C=O). Anal.
Calcd. For C35H38N2O7:
C: 70.21, H: 6.40, N: 4.68. Found: C: 70.10, H: 6.62, N: 4.63.
17 The excess n-butyllithium
(two equivalents) required for the lithiation of 1,
induces the formation of an anion on the acetamide’s methyl
group, which probably attacks the ribonolactone to provide 4.
18 The use of acid labile protecting
groups for the 5-OH of the lactone component (e.g. TBDMS) should
be avoided, since the corresponding 1′,5′-anhydro
derivative is obtained from this reaction as the major product,
irrespective of the reaction conditions
or of the Lewis acid used for catalysis.
19
Krohn K.
Heidi H.
Wielkens K.
J.
Med. Chem.
1992,
35:
511
20 Preparation of 6:
To a solution of the anomers 3 (0.5 g,
0.84 mmol) in dry CH2Cl2 (20 ml) at 0 °C
was added under argon BF3Et2O (0.22 ml, 1.68
mmol). The solution was stirred at 5-10 °C for
5 h and then, was neutralized with a saturated NaHCO3 solution.
The mixture was extracted with CH2Cl2 and
the combined organic extracts were dried (Na2SO4)
and concentrated to dryness. The residue was purified by flash chromatography
(silica gel, 18 × 1 cm) using EtOAc as
the eluent to give 0.46 g (95%) of
an inseparable E/Z mixture of 5.
This mixture was dissolved in absolute EtOH (20 mL) and hydrogenated
(10% Pd/C, 90 mg) at 50 psi for 5 h. The catalyst
was filtered off, washed with EtOH, the solvent was vacuum-evaporated
and the residue was purified by column chromatography (CH2Cl2-MeOH,
97:3, silica gel, 18 × 1 cm), to give 6,
together with the corresponding α-anomer(7). 3-Acetamido-2-methoxy-4-[(β-d-ribofuranosyl)methyl]py-ridine(6): White foam. 250 mg (29%). 1
NMR
(400 MHz, CDCl3) δ 1.98 (s, 3 H, COCH3),
2.53 (dd, 1 H, J = 9.15 Hz, 14.64 Hz, pyCH2),
2.78 (dd, 1 H, J = 4.03 Hz, 14.64 Hz, pyCH2),
3.36 (d, 1 H, J4
′
,5
′ = 5.12
Hz, J5
′
,5
′ = 11.71
Hz, H-5′), 3.41 (d, 1 H, J4
′
,5
′ = 4.03
Hz, J5
′
,5
′ = 11.71
Hz, H-5′), 3.59 (m, 2 H, H-2′, H-4′),
3.81 (m, 5 H, H-1′, H-3′, OCH3), 4.88
(m, 1 H, OH, D2O exchangeable), 5.07 (m, 2 H, 2 × OH, D2O exchangeable),
6.96 (d, 1 H, J5,6 = 5.12 Hz, H-5), 7.93 (d,
1 H, J6,5 = 5.12 Hz, H-6), 9.21 (br s, 1 H,
NHAc, D2O exchangeable). 13C
NMR (50 MHz, CDCl3) δ 22.6 (CH3-CO),
36.0 (pyCH2), 53.6 (OCH3), 61.6 (C-5′),
70.8 (C-3′), 74.62 (C-2′), 81.45 (C-4′),
84.32 (C-1′), 118.7 (C-5), 120.1 (C-3), 143.9 (C-6), 147.6
(C-4), 159.7 (C-2), 169.0 (C=O). Anal. Calcd. for C14H20N2O6:
C: 53.84, H: 6.45, N: 8.97. Found: C: 53.69, H: 6.17, N: 8.76. 3-Acetamido-2-methoxy-4-[(α-d-ribofuranosyl)methyl]pyridine(7): Mp: 187 °C (MeOH). 490 mg
(57%). 1
NMR
(400 MHz, CDCl3) δ 2.02 (s, 3 H, COCH3),
2.72 (dd, 1 H, J = 8.05 Hz, 14.27 Hz, pyCH2),
2.74 (dd, 1 H, J = 5.12 Hz, 14.27 Hz, pyCH2),
3.32 (d, 1 H, J4
′
,5
′ = 5.13
Hz, J5
′
,5
′ = 12.08
Hz, H-5′), 3.48 (d, 1 H, J4
′
,5
′ = 2.20
Hz, J5
′
,5
′ = 12.08
Hz, H-5′), 3.67 (m, 1 H, H-4′), 3.78 (m, 1 H,
H-2′), 3.81 (s, 3 H, OCH3), 3.88 (m, 1 H, H-3′),
4.04 (m, 1 H, H-1′), 4.59 (m, 1 H, OH, D2O exchangeable),
4.84 (m, 2 H, 2 × OH, D2O
exchangeable), 6.98 (d, 1 H, J5,6 = 5.12 Hz,
H-5), 7.92 (d, 1 H, J6,5 = 5.12 Hz, H-6), 9.28
(br s, 1 H, NHAc, D2O exchangeable). 13C
NMR (50 MHz, CDCl3) δ 22.7 (CH3CO),
31.3 (pyCH2), 53.3 (OCH3), 61.7 (C-5′),
71.9 (C-3′), 72.1 (C-2′), 79.1 (C-4′), 81.9
(C-1′), 118.7 (C-5), 120.0 (C-3), 143.5 (C-6), 148.0 (C-4),
159.5 (C-2), 168.5 (C=O). Anal. Calcd. for C14H20N2O6: C:
53.84, H: 6.45, N: 8.97. Found: C: 53.55, H: 6.39, N: 9.11.
21 Data of 12:
Yield: 90%. Mp: 253 °C (dec.) (EtOH). UV (CH3OH) λmax(nm)
(ɛ × 10-3): 302 (8.17),
251 (6.62). 1
NMR (400
MHz, DMSO-d
6) δ 3.48
(m, 2 H, H-5′), 3.81 (m, 1 H, H-4′), 3.95 (m,
1 H, H-3′), 4.12 (m, 1 H, H-2′), 4.81 (d, 1 H, J1
′,2
′ = 6.95
Hz, H-1′), 4.82 (br s, 1 H, D2O exchangeable, OH-5′),
4.89 (br. s., 1 H, D2O exchangeable, OH-3′),
4.98 (br. s., 1 H, D2O exchangeable, OH-2′),
6.68 (d, 1 H, J4,5 = 6.22 Hz, H-4), 6.88 (d,
1 H, J5,4 = 6.22 Hz, H-5), 11.2 (br s, 1 H,
D2O exchangeable, NH-6), 13.8 (br. s., 1 H, D2O exchangeable,
NH-1). 13C NMR (50 MHz, DMSO-d
6) δ 62.2 (C-5′),
71.5 (C-3′), 75.1 (C-2′), 79.5 (C-1′),
85.5 (C-4′), 99.3 (C-4), 123.4 (C-3α), 132.8 (C-7α),
125.4 (C-5), 145.8 (C-3), 154.3 (C-7). Anal. Calcd. for C11H13N3O5:
C: 49.44, H: 4.90, N: 15.72. Found: C: 49.60, H: 5.12, N: 15.51.